Prostate Cancer and Prostatic Diseases

Article	Citations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	84
Best of 2022 in prostate cancer and prostatic diseases	82
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	74
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	65
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer	55
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	54
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study	51
New BPH therapy classification: what really FITs?	49
Germline alterations among Hispanic men with prostate cancer	49
More evidence that physical activity is beneficial for prostate cancer	38
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	36
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes	36
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	35
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	35
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis	35
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	35
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	34
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	33
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	32
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study	30
Concerns regarding prostate cancer screening guidelines in minority populations	30
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer	29
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	29
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions	29
Incidence of prostate cancer in transgender women in the US: a large database analysis	28

Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	28
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer	28
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer	28
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients	27
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms	27
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	27
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	27
Feasibility and safety study of the Flostent™ system (RAPID-I)	26
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	26
TRexit is going one step further	25
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer	25
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database	24
The effects of glycemic index on prostate cancer progression in a xenograft mouse model	24
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	24
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	24
The evolving clinical use of prostate cancer biomarkers	24
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	24
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials	24
Reply to RE: Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?	23
Selective Bone Scan staging for patients with Prostate cancer: do absolute categories really make sense?	23
The times have changed. Let the urologists change!	23
Antimicrobial prophylaxis: To do or not to do? This is the question	22
Methodological concerns regarding KEYNOTE-199: immortal time bias and treatment attribution challenges in combination immunotherapy	22
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy	22
“Targeted microwave ablation: another way to kick the can(cer) down the road?”	21
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)	21
Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature	20
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate	20
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants	20
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction	20
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study	20
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision	20
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	20
Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT	19
Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics	19
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	19
Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey	19
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	19
Association of prostate cancer with human papillomavirus infections: a case-control study	18
Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	18
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK	18
Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system	18
Editorial Expression of Concern: Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells	18
Prognostic value of MR visibility/invisibility in men on Active Surveillance	18
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry	17
Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis	17
Correction: Estimating patient health in prostate cancer treatment counseling	17
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan	17
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT	17
Survivorship in prostate cancer following robotic assisted radical prostatectomy–the time to act is now!	17

A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer	17
The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy	17
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies	17
The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis	17
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	17
Sleep disturbances are underappreciated in prostate cancer survivorship	17
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification	16
Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial	16
Perioperative outcomes comparing the DaVinci 5 with DaVinci Xi in patients undergoing robotic-assisted radical prostatectomy	16
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial	16
Less is more: the “Safety Net Approach” balances precision and safety	15
Risk calculators for the detection of prostate cancer: a systematic review	15
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy	15
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey	15
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study	15
Cardiovascular risk in ADT recipients: does the type of ADT matter?	15
Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape	15
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	15
Re: Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	15
Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications	15
Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?	14
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer	14
MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis	14
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review	14
Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores	14
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials	14
Prevalence and determinants of shared decision-making for PSA testing in the United States	13
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	13
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	13
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer	13
Characteristics of incidental prostate cancer in the United States	13
Negative perceptions of the health system and racial inequities in PSA screening	13
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	13
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	13
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	12
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes	12
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings	12
The impact of race on survival in metastatic prostate cancer: a systematic literature review	12
Quality of information and appropriateness of ChatGPT outputs for urology patients	12
The changing face of castrate resistant prostate cancer	12
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta	12
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	12
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis	12
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	12
Best of 2023 in Prostate Cancer and Prostatic Diseases	12
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?	12
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz	11
Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis	11
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment	11
MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?	11
Biopsy strategies in the era of mpMRI: a comprehensive review	11
Hyperglycemia and microRNAs in prostate cancer	11
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry	11
Surveillance after Focal Therapy – a Comprehensive Review	11
Overcoming barriers to prostate cancer genetic testing: who, when, and how	11
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	11
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)	11
Prostate cancer and prostatic diseases is “Your” journal	11
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?	11
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer	10
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	10
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration	10
Quality of information and appropriateness of Open AI outputs for prostate cancer	10
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH	10
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study	10
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients	10
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis	10
Re: Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP	9
Characterisation of cell lines derived from prostate cancer patients with localised disease	9
The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016	9
15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer	9
New robotic platforms for prostate surgery: the future is now	9
Social determinants of health into evaluations of quality and appropriateness of AI assistant ChatGPT	9
Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis	9
MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in i	9
Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-ΔG carriers	9
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer	9
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	9
Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer	9
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study	9

Best of 2024 in Prostate Cancer and Prostatic diseases	9
Quality of information and appropriateness of ChatGPT outputs for urology patients	9
Relative search popularity of five advanced prostate cancer medications using Google Trends	9
Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis	9
Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	9
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer	9
Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer	9
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer	9
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care	9
Whack-a-met: serial SABR for repeated oligoprogression in metastatic CRPC	9